Vertex Pharmaceuticals Inc (VRTX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$6.56 (-1.41%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Key Insights

Critical company metrics and information
  • Share Price

    $458.93
  • Market Cap

    $118.19 Billion
  • Total Outstanding Shares

    257.53 Million Shares
  • Total Employees

    5,400
  • Dividend

    No dividend
  • IPO Date

    July 31, 1991
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.vrtx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$-842.60 Million
Net Cash Flow From Investing Activities$-3.83 Billion
Net Cash Flow From Investing Activities, Continuing$-3.83 Billion
Net Cash Flow From Operating Activities$-842.60 Million
Net Cash Flow, Continuing$-5.90 Billion
Net Cash Flow$-5.87 Billion
Exchange Gains/Losses$32.10 Million
Net Cash Flow From Financing Activities$-1.22 Billion
Net Cash Flow From Financing Activities, Continuing$-1.22 Billion

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations After Tax$-479.80 Million
Other Operating Expenses$7.97 Billion
Income/Loss From Continuing Operations Before Tax$259.60 Million
Cost Of Revenue$1.48 Billion
Basic Earnings Per Share$1.85
Costs And Expenses$10.90 Billion
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss$-479.80 Million
Income Tax Expense/Benefit$739.40 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Revenues$10.63 Billion
Basic Average Shares$258.10 Million
Benefits Costs and Expenses$10.37 Billion
Selling, General, and Administrative Expenses$1.46 Billion
Net Income/Loss Available To Common Stockholders, Basic$-479.80 Million
Gross Profit$9.15 Billion
Diluted Average Shares$258.20 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Attributable To Parent$-479.80 Million
Operating Income/Loss$-270.40 Million
Operating Expenses$9.42 Billion
Diluted Earnings Per Share$1.90

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Commitments and Contingencies$0.00
Intangible Assets$831.60 Million
Other Non-current Assets$11.60 Billion
Equity Attributable To Parent$15.63 Billion
Inventory$1.08 Billion
Noncurrent Liabilities$2.64 Billion
Equity$15.63 Billion
Assets$22.24 Billion
Liabilities And Equity$22.24 Billion
Current Assets$9.80 Billion
Liabilities$6.61 Billion
Other Current Assets$8.72 Billion
Noncurrent Assets$12.44 Billion
Other Current Liabilities$3.58 Billion
Current Liabilities$3.97 Billion
Accounts Payable$395.80 Million
Equity Attributable To Noncontrolling Interest$0.00

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to Vertex Pharmaceuticals Inc (VRTX)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.